Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
PURPOSE OF REVIEW: A strong positive correlation between plasma apolipoprotein (apo) C-III and triglyceride concentrations has been invariably observed in human and animal studies. The hypertriglyceridemic effect of apo C-III has been conventionally explained by its extracellular roles in inhibiting lipolysis catalysed by lipoprotein lipase and attenuating triglyceride-rich lipoprotein clearance through receptor-dependent and/or independent mechanisms. However, recent experimental evidence suggests that apo C-III may also play an intracellular role in promoting hepatic triglyceride-rich lipoprotein production. RECENT FINDINGS: Kinetic studies with humans and genetically modified mice have shown that apo C-III is linked with increased production of triglyceride-rich lipoproteins, such as very-low-density lipoprotein 1 (VLDL1). Mutational studies on human apo C-III variants (originally identified in humans with hypotriglyceridemia or hyperalphalipoproteinemia) provide the structure-function analysis of human apo C-III, demonstrating that loss-of-function mutations within human apo C-III impair the assembly and secretion of triglyceride-rich VLDL1 under lipid-rich conditions. SUMMARY: The current review summarizes recent experimental evidence for an intrahepatic role of human apo C-III in promoting mobilization and utilization of triglyceride during VLDL1 assembly/secretion. Understanding mechanisms by which hepatic apo C-III expression is regulated under insulin resistance and diabetic conditions will lead to better and more rational strategies for the prevention and treatment of diabetic hypertriglyceridemia that is closely related to premature atherosclerosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Experimental studies show that apoCIII enhances hepatic assembly and secretion of VLDL, and human kinetic studies have shown an association between apoCIII and VLDL production [47].”
In the citing paper
“Apo C-III is expressed both intestinally and hepatically, circulates with TG-rich lipoproteins, has net deleterious effects on lipoprotein metabolism58–63”
From Clinical review on triglycerides (2020) · cites this paper as [60]
Citations
Cites
Donnelly, K. L., Smith, C. I., Schwarzenberg, S. J., Jessurun, J., Boldt, M. D., & Parks, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23621 · Cited by 3,604 · cited 2×
“fatty acids of adipocyte origin or released from hydrolysis of remnant lipoproteins), as well as endogenous de-novo lipogenesis (DNL), are the major substrate for hepatic triglyceride synthesis [13].”
BackgroundSelective versus Total Insulin Resistance: A Pathogenic Paradox
Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 965 · cited 1×
“Second, the FoxO1 branch of the insulin signalling becomes insensitive to insulin, whereas the DNL (controlled by the SREBP-1c pathway) remains responsive [13,52].”
BackgroundAdiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820 · cited 1×
“2b), a hallmark for diabetic hypertriglyceridemia [54] that often occurs at the initial stage of insulin resistance [55].”
BackgroundPollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688 · cited 1×
“On the contrary, loss-of-function mutations within the human APOC3 gene have been associated with hypotriglyceridemia [5], hyperalphalipoproteinemia [6], and cardioprotective lipid/lipoprotein profiles in the Old Order Amish population [7].”
BackgroundSacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490 · cited 1×
“VLDL or LDL containing apo C-III imposes a greater risk to cardiovascular complications [21].”
BackgroundApolipoprotein C3 gene variants in nonalcoholic fatty liver disease
Petersen, K. F., Dufour, S., Hariri, A., Nelson-Williams, C., Foo, J. N., Zhang, X.-M., Dziura, J., Lifton, R. P., & Shulman, G. I. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907295 · Cited by 428
Mode of Action of Peroxisome Proliferators as Hypolipidemic Drugs.
Hertz, R., Bishara-Shieban, J., & Bar-Tana, J. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13470 · Cited by 339 · cited 1×
“Unau 0957-9672 2012 Wolters Kluwer Health | Lippincott Williams & Wilk Negative regulators include peroxisome proliferator-activated receptor-a [35], peroxisome proliferator-activated receptor-g [36], farnesoid X receptor [37] and Rev-erba [38].”
BackgroundMaeda, N., Li, H., Lee, D., Oliver, P., Quarfordt, S. H., & Osada, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31559-4 · Cited by 313 · cited 1×
“Unautho been observed in Apoc3-null mice [8].”
Foxo1 mediates insulin action on apoC-III and triglyceride metabolism
Altomonte, J., Lin, C., Harbaran, S., Richter, A. M., Xu, J., Meseck, M. L., & Dong, H. H. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19992 · Cited by 309 · cited 3×
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
BackgroundFoxO1 mediates insulin-dependent regulation of hepatic VLDL production in mice
Kamagate, A., Qu, S., Perdomo, G., Su, D., Kim, D. H., Slusher, S., Meseck, M., & Dong, H. H. (2008) · Journal of Clinical Investigation · doi:10.1172/jci32914 · Cited by 282 · cited 2×
“Fourth, the dysregulated FoxO1 signalling is unable to attenuate MTP and apo C-III expression [41,47].”
Background
Cited by
Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease
Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919
Sugar consumption, metabolic disease and obesity: The state of the controversy
Stanhope, K. L. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1084990 · Cited by 739
“Hepatic insulin resistance may also indirectly increase VLDL production and secretion by 1) increasing apolipoprotein B (apoB) availability (42, 43), the protein backbone of VLDL; 2) up-regulating microsomal triglyceride-transfer protein expression (41), which catalyzes the assembly of TG and apoB into VLDL; and 3) in…”
Clinical review on triglycerides
Laufs, U., Parhofer, K. G., Ginsberg, H. N., & Hegele, R. A. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz785 · Cited by 544
Targeting APOC3 in the familial chylomicronemia syndrome
Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491
New insights into the pathophysiology of dyslipidemia in type 2 diabetes
Taskinen, M.-R., & Borén, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.01.039 · Cited by 440
“In a series of publications, Yao and coworkers have unraveled an intracellular role of apo-CIII in promoting hepatic VLDL1 secretion [144,149,150].”
BackgroundGraham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377
“Plasma triglyceride are complex lipids primarily transported on very low–density lipoprotein (VLDL) particles and chylomicrons that are synthesized in the liver and intestine, respectively.(11) The plasma triglyceride concentration is a complex polygenic trait, but a variety of genetic determinants have been identifie…”
BackgroundSiri-Tarino, P. W., Chiu, S., Bergeron, N., & Krauss, R. M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034449 · Cited by 268
Selective Hepatic Insulin Resistance, VLDL Overproduction, and Hypertriglyceridemia
Sparks, J. D., Sparks, C. E., & Adeli, K. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.241463 · Cited by 231
“Formation of intraluminal lipid droplets requires MTP,(8) and droplets can be stabilized by apoC-III.(11) In insulin resistant states, loss of insulin suppression of apoB secretion occurs before global hepatic insulin resistance,(12,13) consistent with the findings of Sorensen et al(14) where insulin”
ResultEctopic lipid storage and insulin resistance: a harmful relationship
Borén, J., Taskinen, M. ‐., Olofsson, S. ‐., & Levin, M. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12071 · Cited by 234
Lipoprotein Metabolism, Dyslipidemia, and Nonalcoholic Fatty Liver Disease
Fisher, E., & Cohen, D. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358519 · Cited by 179
“Insulin suppresses VLDL particle secretion rates by several mechanisms (25, 42).”
BackgroundInfluentialLipid-Lowering Agents: Targets Beyond PCSK9
Hegele, R. A., & Tsimikas, S. (2019) · Circulation Research · doi:10.1161/circresaha.118.313171 · Cited by 171
Wilson, J. M., Nikooienejad, A., Robins, D. A., Roell, W. C., Riesmeyer, J. S., Haupt, A., Duffin, K. L., Taskinen, M., & Ruotolo, G. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14174 · Cited by 164
Oscarsson, J., & Hurt-Camejo, E. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0541-3 · Cited by 158
“Experimental studies show that apoCIII enhances hepatic assembly and secretion of VLDL, and human kinetic studies have shown an association between apoCIII and VLDL production [47].”
BackgroundLi, Y., Song, Z. X., Yin, H., Wang, Y. Y., Shu, G., Lu, H. X., Wang, S. K., & Sun, G. J. (2015) · Lipids · doi:10.1007/s11745-015-4091-z · Cited by 172
“Elevated plasma ApoC3 protein has several pro-atherogenic properties, such as inhibiting the lipolysis of TAGrich lipoproteins [32] and increasing the formation of atherogenic small dense LDL [33].”
BackgroundSelf-citationObstructive sleep apnea and dyslipidemia: from animal models to clinical evidence
Barros, D., & Rio, F. G. (2018) · SLEEP · doi:10.1093/sleep/zsy236 · Cited by 144
“The subsequent flow of FFA to the liver provides substrate for the creation of VLDL rich in triglycerides and its later release into the systemic circulation [102].”
BackgroundPostprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
Hiyoshi, T., Fujiwara, M., & Zemin, Y. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160164 · Cited by 126
“Recently, the apoC-III functionality has resurged as a main topic in lipid and lipoprotein metabolism([61]).”
BackgroundProteomic Analysis of Human Plasma during Intermittent Fasting
Harney, D., Hutchison, A. T., Hatchwell, L., Humphrey, S. J., James, D. E., HOCKING, S. L., Heilbronn, L. K., & Larance, M. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00090 · Cited by 116
Genetically Modified Pig Models for Human Diseases
Fan, N., & Lai, L. (2013) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2012.07.014 · Cited by 108
Sullivan, E. M., Pennington, E. R., Green, W. D., Beck, M. A., Brown, D. A., & Shaikh, S. R. (2018) · Advances in Nutrition · doi:10.1093/advances/nmy007 · Cited by 115
The Importance of Lipoprotein Lipase Regulation in Atherosclerosis
Kumari, A., Kristensen, K. K., Ploug, M., & Winther, A.-M. L. (2021) · Biomedicines · doi:10.3390/biomedicines9070782 · Cited by 115
“ApoC-III assists in the intracellular synthesis, assembly, and secretion of VLDLs [138].”
BackgroundInfluentialCrosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
Lim, S. K., Taskinen, M., & Borén, J. (2018) · Obesity Reviews · doi:10.1111/obr.12820 · Cited by 111
“APO‐C3 is an apolipoprotein that inhibits lipoprotein lipase (LPL) and plays a crucial role in lipid metabolism.(139) An APO‐C3 gain‐of‐function variant associates with the risks of atherosclerotic diseases including ischaemic stroke and coronary heart disease.”
BackgroundTaskinen, M.-R., & Borén, J. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0614-1 · Cited by 90
Stanhope, K. L., Goran, M. I., Bosy‐Westphal, A., King, J. C., Schmidt, L. A., Schwarz, J. ‐., Stice, E., Sylvetsky, A. C., Turnbaugh, P. J., Bray, G. A., et al. (2018) · Obesity Reviews · doi:10.1111/obr.12699 · Cited by 87
“and apolipoprotein CIII synthesis (339) and by up-regulating microsomal TG transfer protein expression (MTP) (336).”
BackgroundWilliams, K. J., & Wu, X. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.02.004 · Cited by 87
“Thus, insulin-induced suppression of apoC-III inhibits VLDL1 secretion [299, 300].”
BackgroundAmyloid-Forming Properties of Human Apolipoproteins: Sequence Analyses and Structural Insights
Das, M., & Gursky, O. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-17344-3_8 · Cited by 92
“ApoC-I inhibits cholesterol ester transfer protein, apoC-II is a physiological activator of lipoprotein lipase, while apoCIII is its inhibitor and is also implicated in VLDL production (Jong et al. 1999; Shachter 2001; Yao and Wang 2012; Kei et al. 2012).”
BackgroundOral, E. A., Garg, A., Tami, J., Huang, E. A., O'Dea, L. S. L., Schmidt, H., Tiulpakov, A., Mertens, A., Alexander, V. J., Watts, L., et al. (2022) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2022.08.008 · Cited by 71
Effects of bariatric surgery on lipid-lipoprotein profile
Piché, M., Tardif, I., Auclair, A., & Poirier, P. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154441 · Cited by 77
Martínez-Cerón, E., Casitas, R., Galera, R., Sánchez-Sánchez, B., Zamarrón, E., García‐Sánchez, A., Oriol, A. J., Cubillos‐Zapata, C., & Rio, F. G. (2021) · Sleep Medicine · doi:10.1016/j.sleep.2021.05.012 · Cited by 62
Allard, J., Bucher, S., Massart, J., Ferron, P.-J., Le Guillou, D., Loyant, R., Daniel, Y., Launay, Y., Buron, N., Begriche, K., et al. (2021) · Cell Biology and Toxicology · doi:10.1007/s10565-020-09537-1 · Cited by 51
“…and enzymes playing a significant role in VLDL assembly, in particular APOB, APOC3, MTTP, and ANGPTL3 (Fisher et al. 2014; Wang et al. 2015; Yao and Wang 2012); (3) these effects were associated with ER stress as assessed by mRNA level of BIP, CHOP, IRE1α, PERK, and ATF6; (4) the…”
BackgroundRole of apolipoprotein C-III overproduction in diabetic dyslipidaemia
Adiels, M., Taskinen, M., Björnson, E., Andersson, L., Matikainen, N., Söderlund, S., Kahri, J., Hakkarainen, A., Lundbom, N., Sihlbom, C., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13744 · Cited by 55
All Low-Density Lipoprotein Particles Are Not Created Equal
Krauss, R. M. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.114.303458 · Cited by 59
Zheng, C. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000040 · Cited by 50
Microsome-associated lumenal lipid droplets in the regulation of lipoprotein secretion
Yao, Z., Zhou, H., Figeys, D., Wang, Y., & Sundaram, M. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835aebe7 · Cited by 46
“In this regard, formation of bulk triglyceride droplets, together with associated proteins, is also activated under nutrient-rich conditions in close association with microsome lumen [2].”
BackgroundInfluentialSelf-citationNon-alcoholic fatty liver disease: a narrative review of genetics
Christopher, J., Zemin, Y., & Z., G. (2018) · The Journal of Biomedical Research · doi:10.7555/jbr.32.20180045 · Cited by 45
“Apolipoprotein C3 (apoC3) is a major constituent of VLDL particles and promotes triglyceride-rich VLDL assembly and secretion([66]).”
BackgroundJattan, J., Rodia, C., Li, D., Diakhate, A., Dong, H., Bataille, A., Shroyer, N. F., & Kohan, A. B. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071340 · Cited by 42
“In plasma, apoC-III resides on both TAGrich lipoproteins and HDLs. Overproduction of apoC-III and TAG-rich lipoproteins is a common feature in patients with hypertriglyceridemia (10, 11). apoC-III also stimulates hepatic synthesis and secretion of VLDLs (12, 13).”
BackgroundInfluentialSundaram, M., Curtis, K. R., Amir Alipour, M., LeBlond, N. D., Margison, K. D., Yaworski, R. A., Parks, R. J., McIntyre, A. D., Hegele, R. A., Fullerton, M. D., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m077313 · Cited by 38
“The plasma apoC-III concentration is positively correlated with the plasma triacylglycerol (TAG) concentrations, and elevated plasma apoC-III is invariably associated with hypertriglyceridemia (3).”
BackgroundSelf-citationGoyal, S., Tanigawa, Y., Zhang, W., Chai, J. F., Almeida, M., Sim, X., Lerner, M. R., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01531-8 · Cited by 48
Orho‐Melander, M. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12407 · Cited by 35
Zheng, J. J., Agus, J., Hong, B. V., Tang, X., Rhodes, C. H., Houts, H. E., Zhu, C., Kang, J. W., Wong, M., Xie, Y., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-95451-3 · Cited by 44
Hibert, P., Mirebeau‐Prunier, D., Beseme, O., Chwastyniak, M., Tamareille, S., Pinet, F., & Prunier, F. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085669 · Cited by 40
“Involved in triglyceride-rich lipoprotein clearance and catabolism, ApoC-III is associated with hypertriglyceridemia, type-I diabetes, and coronary heart diseases [48–50].”
BackgroundKegulian, N. C., Ramms, B., Horton, S. B., Trenchevska, O., Nedelkov, D., Graham, M. J., Lee, R. G., Esko, J. D., Yassine, H. N., & Gordts, P. L. S. M. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312723 · Cited by 38
Population serum proteomics uncovers a prognostic protein classifier for metabolic syndrome
Cai, X., Xue, Z., Zeng, F., Tang, J., Yue, L., Wang, B., Ge, W., Xie, Y., Miao, Z., Gou, W., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101172 · Cited by 42
APOC3 siRNA and ASO therapy for dyslipidemia
Chebli, J., Larouche, M., & Gaudet, D. (2024) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000857 · Cited by 35
“The contribution of apoC3 to VLDL or chylomicron & chylomicron assembly and secretion is mitigated [9,10 ].”
BackgroundLipid and Lipoprotein Metabolism in Liver Disease
Arvind, A., Osganian, S. A., Cohen, D. E., & Corey, K. E. (2015) · MDText.com, Inc. eBooks · Cited by 37
Increased Hepatic Lipogenesis Elevates Liver Cholesterol Content
Berger, J.-M., & Moon, Y.-A. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.2147 · Cited by 38
“Apoc3 mRNA expression was slightly elevated in the liver of the mice fed the FF/HS diet (Supplementary Fig.”
Hypertriglyceridemia Acute Pancreatitis: Animal Experiment Research
Wang, L., Xu, T., Wang, R., Wang, X., & Wu, D. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06928-0 · Cited by 34
“1 3 triglyceride concentrations has been invariably observed [62].”
BackgroundDietary fructose and dyslipidemia: new mechanisms involving apolipoprotein CIII
Hieronimus, B., & Stanhope, K. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000653 · Cited by 34
Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31
“There is also substantial evidence that apoC-III plays a role in hepatic TG-rich lipoprotein production (31).”
BackgroundAromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition
Meyers, N. L., Larsson, M., Vorrsjö, E., Olivecrona, G., & SMALL, D. M. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m071126 · Cited by 30
“In fact, animal and human studies have established a strong, positive correlation between elevated plasma apoC-III levels and TG levels, which are an independent risk factor for atherosclerotic CVD (1, 8).”
BackgroundInfluentialShi, J., Yang, H., Duan, X., Li, L., Sun, L., Li, Q., & Zhang, J. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2016.57.3.549 · Cited by 29
“ApoC-III also affects liver production of lipoproteins, probably by inducing the expression of microsomal triglyceride transfer protein.(27) Apart from the wellcharacterized function of ApoC-III in triglyceride metabolism and insulin resistance, emerging evidence suggests that ApoCIII is also linked to various cancers.”
BackgroundDrenos, F., Davey Smith, G., Ala-Korpela, M., Kettunen, J., Würtz, P., Soininen, P., Kangas, A. J., Dale, C., Lawlor, D. A., Gaunt, T. R., et al. (2016) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.115.001302 · Cited by 26
“To date, epidemiological studies have not had the required information to assess the molecular mechanisms involved, and despite the consensus that APOC3 is affecting the TLRs, small in vivo and in vitro studies have not determined the relative importance of the different mechanisms(20) and how specific mutations of th…”
MethodWang, Y., Yin, X., Li, L., Deng, S., & He, Z. (2016) · PLoS ONE · doi:10.1371/journal.pone.0163910 · Cited by 25
Self-citationNon-alcoholic fatty liver disease–a chronic disease of the 21st century
Metrakos, P. P., & Tommy, N. (2017) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160153 · Cited by 28
“Sustained hyperinsulinemia and hyperglycemia with compromised insulin/IRS2/ FOXO1 signaling yields high expression of MTP and apoC-III with an overproduction of TG-VLDL1 [52,75-79]”
BackgroundRole of apolipoproteins in the pathogenesis of obesity
Huang, M., Zheng, J., Chen, L., You, S., & Huang, H. (2023) · Clinica Chimica Acta · doi:10.1016/j.cca.2023.117359 · Cited by 23
Gene-based therapies in lipidology: current status and future challenges
Gaudet, D., & Brisson, D. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000240 · Cited by 20
“ApoC-III has also been reported to inhibit hepatic lipase activity [20], promote intrahepatic VLDL assembly and secretion [21], and inhibit hepatic clearance of triglyceride-rich lipoprotein remnants [22].”
BackgroundKarwatowska‐Prokopczuk, E., Lesogor, A., Yan, J., Hoenlinger, A., Margolskee, A., Li, L., & Tsimikas, S. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02297-5 · Cited by 19
“Apolipoprotein C-III (apoC-III) is a glycoprotein secreted by the intestine and liver that binds to triglyceride-rich lipoproteins (TRLs), such as chylomicrons, very-low-density lipoprotein (VLDL), and their remnants [1, 2].”
BackgroundYao, Z., Zhang, L. R., & Ji, G. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60023-6 · Cited by 20
Self-citationDing, X., Yang, Z., Han, Y., & Yu, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109554 · Cited by 19
“Animal and human studies have shown a strong positive correlation between plasma apoC3 and triglyceride concentrations, and ApoC3 transgenic mice show severe hypertriglyceridemia [22].”
BackgroundCannabis effects on lipoproteins
Lazarte, J., & Hegele, R. A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000575 · Cited by 18
Pathobiology of Obstructive Sleep Apnea-Related Dyslipidemia: Focus on the Liver
Mirrakhimov, A. E., & Ali, A. M. (2013) · ISRN Cardiology · doi:10.1155/2013/687069 · Cited by 20
“Subsequent FFA in�ux into the liver may lead to the assembly of TG-rich VLDL and their further efflux into the systemic circulation [34].”
BackgroundAn overview of persistent chylomicronemia: much more than meets the eye
Larouche, M., Watts, G. F., Ballantyne, C. M., & Gaudet, D. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000903 · Cited by 17
Development of Antisense Drugs for Dyslipidemia
Yamamoto, T., Wada, F., & Harada‐Shiba, M. (2016) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.rv16001 · Cited by 19
Key differences between apoC-III regulation and expression in intestine and liver
West, G., Rodia, C. N., Li, D., Johnson, Z. K., Dong, H., & Kohan, A. B. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.116 · Cited by 19
“This is paradoxical to both the triglyceride-raising role apoC-III plays in the plasma, and cell culture data suggesting that intracellular apoC-III promotes the synthesis and secretion of larger, more triglyceride-rich VLDL from the liver [17,18,27].”
BackgroundFTY720 Attenuates Acute Pancreatitis in Hypertriglyceridemic Apolipoprotein CIII Transgenic Mice
Liu, J., Xu, P., Zhang, L., Kayoumu, A., Wang, Y., Wang, M., Gao, M., Zhang, X., Wang, Y., & Liu, C. (2015) · Shock · doi:10.1097/shk.0000000000000400 · Cited by 16
“Apolipoprotein CIII is a natural inhibitor of LPL, and many clinical reports showed that HTG is associated with high ApoCIII level in patients_ plasma (11).”
BackgroundSelf-citationMaraninchi, M., Padilla, N., Béliard, S., Berthet, B., Nogueira, J. P., Dupont-Roussel, J., Mancini, J., Corroller, A. B., Dubois, N., Grangeot, R., et al. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.02.012 · Cited by 16
Kassai, A., Muniyappa, R., Levenson, A. E., Walter, M. F., Abel, B. S., Ring, M., Taylor, S. I., Biddinger, S. B., Skarulis, M. C., Görden, P., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3891 · Cited by 15
Inhibition of Angiopoietin-Like Protein 3 or 3/8 Complex and ApoC-III in Severe Hypertriglyceridemia
Larouche, M., Khoury, É., Brisson, D., & Gaudet, D. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01179-y · Cited by 15
“ApoC-III plays a role in VLDL assembly/secretion and decreases remnants clearance from the bloodstream [55].”
Li, F.-H., Wang, Y., Liu, X., & Xu, Q. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.122 · Cited by 14
Self-citationRetractedFlorentin, M., Kostapanos, M. S., Anagnostis, P. G., & Liamis, G. L. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1691523 · Cited by 15
Lightbourne, M., Wolska, A. T., Abel, B. S., Rother, K. I., Walter, M. F., Kushchayeva, Y. S., Auh, S., Shamburek, R. D., Remaley, A. T., Muniyappa, R., et al. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa191 · Cited by 11
“ANGPTL8 expression has been shown to be increased by glucose, insulin, and the incretin glucagon-like peptide-1 [51-53].”
BackgroundProspect and progress of gene therapy in treating atherosclerosis
Kivelä, A. M., Huusko, J., & Ylä‐Herttuala, S. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1084282 · Cited by 12
“ApoCIII regulates lipid metabolism through multiple mechanisms such as by inhibiting clearance of VLDL [26] and by affecting liver production of lipoproteins [27].”
BackgroundBiotechnology Approaches for the Treatment of Dyslipidemia
Parolini, C. (2020) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07017-6 · Cited by 10
“Indeed, by inhibiting LPL activity and the hepatic uptake of TRL, it is a determinant of the TG plasma concentrations [131, 132].”
BackgroundTherapeutic inhibition of apoC-III for the treatment of hypertriglyceridemia
Bell, T. A., Graham, M. J., Baker, B. F., & Crooke, R. M. (2015) · Clinical Lipidology · doi:10.2217/clp.15.7 · Cited by 10
Zhu, J., Zhu, X., Shi, C., Li, Q., Jiang, Y., Chen, X., Sun, P., Jin, Y., Wang, T., & Chen, J. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03457-4 · Cited by 8
“It promotes the assembly and secretion of very low-density lipoprotein 1 within cells and inhibits hydrolysis and clearance of tri-glyceride-rich lipoproteins outside cells [62, 63].”
BackgroundMechanistic insights from combining genomics with metabolomics
Drenos, F. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000393 · Cited by 7
Advances in diagnosis and potential therapeutic options for familial chylomicronemia syndrome
Benes, L. B., Brandt, E. J., & Davidson, M. H. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1419863 · Cited by 6
“Apolipoprotein C3 has been shown to inhibit hepatic lipase and promote hepatic VLDL production [57,58].”
BackgroundRen, Y., Li, X., Han, G., Wang, M., Xi, M., Shen, J., Li, Y., & Li, C. (2021) · Poultry Science · doi:10.1016/j.psj.2021.101184 · Cited by 7
Emerging drugs for hyperlipidaemia: an update
Florentin, M., Kostapanos, M. S., Kei, A. A., & Elisaf, M. (2014) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.976553 · Cited by 5
“It also promotes intrahepatic VLDL assembly and secretion [93], reducing triglyceride-rich lipoprotein clearance and increasing the formation of atherogenic sdLDL.”
BackgroundHuman Plasma Lipoprotein Metabolism
Pownall, H. J., Rosales, C., Gillard, B. K., Moon, J. E., & Gotto, A. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-28786-9.00001-3 · Cited by 7
den Hollander, B., Brands, M. M. M. G., Nijhuis, I. J. M., van Troostwijk, L. J. A. E. D., van Essen, P., Hofsteenge, G. H., Koot, B. G. P., Müller, A. R., Tseng, L. A., Stroes, E. S. G., et al. (2024) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2024.108347 · Cited by 4
Lipoproteins: A Source of Cardiac Lipids
Drosatos, K., & Goldberg, I. J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1227-8_2 · Cited by 4
de Loock, A. V., Vandecauter, J., Ullrich, M., Lievens, E., Schroé, H., Moreno‐Justicia, R., Weyns, A., Thienen, R. V., Calders, P., Deshmukh, A. S., et al. (2025) · The Journal of Physiology · doi:10.1113/jp289240 · Cited by 2
A Differential Protein Study on Bronchoalveolar Lavage Fluid at Different Stages of Silicosis
Zhang, X., Han, K., Kan, L., Zhang, Z., Gong, Y., Xiao, S., Bai, Y., Liu, N., Meng, C., Qi, H., et al. (2024) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073260760231023055036 · Cited by 2
The Liver in Metabolic Syndrome
D’Amore, S., Palasciano, G., & Moschetta, A. (2013) · Springer eBooks · doi:10.1007/978-3-319-01008-3_3 · Cited by 3
Valéro, R. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.06.013 · Cited by 2
Gaudet, D. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00035-2 · Cited by 2
Joshy, J., Javed, A., Singh, M. K., Singh, B., Kumar, R., & Hussain, S. (2025) · Cureus · doi:10.7759/cureus.96715 · Cited by 5
Hypertriglyceridemia: diagnostic issues, therapeutic strategies
Bakaleiko, V. V., Reutova, O. V., Алиева, М. С., Baratashvili, G. G., Kostareva, A. A., & Alieva, A. S. (2024) · Russian Journal for Personalized Medicine · doi:10.18705/2782-3806-20244-3-194-205 · Cited by 1
Apolipoprotein Gene Structure and Function
Martín-Campos, J. M., Chang, B. H.-J., Blanco‐Vaca, F., Chan, L., & Julve, J. (2017) · Wiley eBooks · doi:10.1002/9780470015902.a0005909.pub3 · Cited by 1
Petitjean, K. (2022) · theses.fr (ABES) · doi:10.70675/7f7c7395z670az48bdza5e6zbe84bbe6a5f7 · Cited by 2
West, G. (2017) · OpenCommons - UConn (University of Connecticut)
Gao, X., You, L., Liu, A., Sang, X., Li, T., Zhang, S., Li, K., Huang, G., Wang, T., & Xu, A. (2019) · Journal of Traditional Chinese Medical Sciences · doi:10.1016/j.jtcms.2019.11.004
Ramirez‐Cisneros, A., Stefanakis, K., & Mantzoros, C. S. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16194
“21 Elevated levels of APOC3 can lead to hypertriglyceridaemia by inhibiting LPL and preventing apoli-poprotein E-mediated clearance of triglyceride-rich lipoproteins in the liver.”
Apolipoproteins and cardiovascular diseases
Kaur, A., Saha, S., Ujjainiya, R., Ray, A., Basak, T., & Sengupta, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00032-4
Proposed mechanisms of action of serum triglyceride lowering by plant sterols and stanols
Oranje, R. P. A. (2014) · Utrecht University Repository (Utrecht University)
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J.-F., Almeida, M., Sim, X., Lerner, M., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16655697
Zheng, J. (2024) · eScholarship (California Digital Library)
Metadata
- Authors
- Yao, Z., & Wang, Y.
- Affiliations
- University of Ottawa (CA)
- Corresponding author
- Yao, Zemin
- Venue
- Current Opinion in Lipidology
- Published
- 2012-06
- Volume
- 23
- Issue
- 3
- Pages
- 206-212
- ISSN
- 0957-9672 (ISSN-L)
- OpenAlex
- W2041953515
- Cited by
- 100
- References
- 60
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 8 · 2020: 7 · 2019: 9 · 2018: 7 · 2017: 11 · 2016: 8 · 2015: 12 · 2014: 10 · 2013: 7 · 2012: 2
- FWCI
- 1.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Opinion in Lipidology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Heart and Stroke Foundation of Canada
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Keywords
- apolipoprotein C-III, hypertriglyceridemia, hypotriglyceridemia, hyperalphalipoproteinemia, insulin resistance, diabetes mellitus, triglyceride mobilization, lipoprotein lipase
- MeSH terms
- Animals, Gene Expression Regulation, Homeostasis, Humans, Liver, Triglycerides, Apolipoprotein C-III
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.